Orchid Pharma (ORCHPHARMA) Fundamentals 2026 — P/E 249.6x, Revenue Analysis | SniperIQ
Orchid Pharma (ORCHPHARMA) is a India-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₹5,089 Crore, trading at ₹1001.45 on the BSE. This SniperIQ fundamentals page covers Orchid Pharma's valuation (P/E 249.6x, P/B 3.9x), profitability (net margin 2.5%), revenue (₹811 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Orchid Pharma's market cap?
Orchid Pharma (ORCHPHARMA) has a market capitalization of approximately ₹5,089 Crore, trading at ₹1001.45 on the BSE. Market cap moves with the live share price.
What is Orchid Pharma's P/E ratio?
Orchid Pharma's trailing twelve-month P/E ratio is 249.6x, with a price-to-book (P/B) of 3.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Orchid Pharma?
Orchid Pharma runs a net profit margin of 2.5%, a gross margin of 31.5%, and an operating margin of 5.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Orchid Pharma generate?
Orchid Pharma reported revenue of ₹811 Crore for fiscal year 2026, with net income of ₹21 Crore and earnings per share (EPS) of 4.05. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Orchid Pharma pay a dividend?
Orchid Pharma does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Orchid Pharma financially healthy?
Orchid Pharma carries a debt-to-equity ratio of 0.28x and a current ratio of 2.45x, with a market beta of 1.65. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Orchid Pharma a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Orchid Pharma (ORCHPHARMA) the key facts are: market cap ₹5,089 Crore, P/E 249.6x, revenue ₹811 Crore, 52-week range 471.3-1120. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Orchid Pharma's full fundamentals live
Get Orchid Pharma's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.